Related Experiment Video
Updated: Feb 8, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Oncogene addicted non-small-cell lung cancer: current standard and hot topics
Silvia Vecchiarelli1, Chiara Bennati1
1Onco-Hematology Department, S Maria delle Croci Hospital, viale Randi 5, 48121, Ravenna, Italy.
Abstract:
Lung cancer is the leading cause of cancer mortality worldwide. Activating mutations in the EGFR and rearrangements in the anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) genes have been identified as oncogenic drivers in non-small-cell lung cancer. Development of specific small-molecule tyrosine kinase inhibitors, able to interfere with tumor growth and metastatic spread, dramatically changed the natural history of oncogene-addicted non-small-cell lung cancer. However, despite advances in targeted therapies, all patients inevitably develop acquired resistance to tyrosine kinase inhibitors. Novel promising and effective treatments are under investigations.
Insights
Lung cancer remains a leading cause of death. Targeted therapies for EGFR, ALK, and ROS1 in non-small cell lung cancer are effective but lead to acquired resistance, necessitating new treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Lung cancer is the primary cause of cancer-related mortality globally.
- Specific genetic alterations like EGFR mutations and ALK/ROS1 rearrangements drive non-small cell lung cancer (NSCLC) growth.
- Small-molecule tyrosine kinase inhibitors (TKIs) targeting these drivers have transformed NSCLC treatment.
Purpose of the Study:
- To review the current landscape of targeted therapies for oncogene-driven NSCLC.
- To highlight the challenge of acquired resistance to TKIs in NSCLC.
- To discuss the ongoing investigation of novel therapeutic approaches for resistant NSCLC.
Main Methods:
- Literature review of preclinical and clinical studies on targeted therapies for NSCLC.
- Analysis of mechanisms underlying acquired resistance to EGFR, ALK, and ROS1 inhibitors.
- Examination of emerging treatment strategies and investigational drugs.
Main Results:
- Targeted TKIs have significantly improved outcomes for patients with specific genetic alterations in NSCLC.
- Acquired resistance to TKIs is an inevitable challenge, limiting long-term efficacy.
- Various resistance mechanisms have been identified, including secondary mutations and pathway reactivation.
- New generations of TKIs and combination therapies are showing promise in overcoming resistance.
Conclusions:
- Targeted therapy has revolutionized NSCLC treatment, but acquired resistance remains a critical clinical problem.
- Understanding resistance mechanisms is crucial for developing next-generation therapies.
- Ongoing research into novel treatments offers hope for patients with advanced, resistant NSCLC.
Related Concept Videos
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Hot Weather Concreting
Mitigating the heat increase in concrete can be economically achieved by shading aggregate stockpiles to prevent heating from solar radiation,...
Drug Abuse and Addiction: Pharmacological Phenomena
Measurement: Standard Units
Lung Capacity
Standard Electrode Potentials

